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Abstract
Background: Individuals of the same chronological age display different rates of biological ageing. A number of
measures of biological age have been proposed which harness age-related changes in DNA methylation profiles.
These measures include five ‘epigenetic clocks’ which provide an index of how much an individual’s biological age
differs from their chronological age at the time of measurement. The five clocks encompass methylation-based
predictors of chronological age (HorvathAge, HannumAge), all-cause mortality (DNAm PhenoAge, DNAm GrimAge)
and telomere length (DNAm Telomere Length). A sixth epigenetic measure of ageing differs from these clocks in
that it acts as a speedometer providing a single time-point measurement of the pace of an individual’s biological
ageing. This measure of ageing is termed DunedinPoAm. In this study, we test the association between these six
epigenetic measures of ageing and the prevalence and incidence of the leading causes of disease burden and
mortality in high-income countries (n ≤ 9537, Generation Scotland: Scottish Family Health Study).
Results: DNAm GrimAge predicted incidence of clinically diagnosed chronic obstructive pulmonary disease (COPD),
type 2 diabetes and ischemic heart disease after 13 years of follow-up (hazard ratios = 2.22, 1.52 and 1.41,
respectively). DunedinPoAm predicted the incidence of COPD and lung cancer (hazard ratios = 2.02 and 1.45,
respectively). DNAm PhenoAge predicted incidence of type 2 diabetes (hazard ratio = 1.54). DNAm Telomere
Length associated with the incidence of ischemic heart disease (hazard ratio = 0.80). DNAm GrimAge associated
with all-cause mortality, the prevalence of COPD and spirometry measures at the study baseline. These associations
were present after adjusting for possible confounding risk factors including alcohol consumption, body mass index,
deprivation, education and tobacco smoking and surpassed stringent Bonferroni-corrected significance thresholds.
Conclusions: Our data suggest that epigenetic measures of ageing may have utility in clinical settings to
complement gold-standard methods for disease assessment and management.
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Background
The sustained increase in global life expectancy and
population size has prompted a concomitant elevation in
the prevalence of chronic disease states [1]. The World
Health Organisation specifies ten leading causes of
mortality and ten leading causes of disease burden. In
high-income countries, six diseases are present in both
sets: ischemic heart disease, stroke, lung cancer, Alzhei-
mer’s disease (AD) and other dementias, diabetes and
chronic obstructive pulmonary disease (COPD). The
remaining four leading causes of mortality are lower re-
spiratory tract diseases, bowel cancer, kidney disease and
breast cancer [2]. The additional four causes of disease
burden are back or neck pain, skin disease, sense organ
disease and depression [3]. Many of these disease states
encompass heterogeneous, complex aetiologies resulting
in a paucity of effective treatment paradigms. Given the
number of individuals affected by such disorders and the
associated burden, there is an urgent need for effective
molecular predictors in clinical settings that can identify
individuals on trajectories towards disease.
Ageing is a major risk factor for many common
disease states. However, individuals of the same chrono-
logical age exhibit disparate rates of biological ageing
and susceptibilities to common morbidities and mortal-
ity. Differential patterns of biological ageing among indi-
viduals may be exploited to identify novel predictors of
disease [4]. Recently, a number of strategies have been
proposed to estimate biological age by leveraging inter-
individual variation in DNA methylation (DNAm)
profiles. These epigenetic measures of ageing, many of
which are called ‘epigenetic clocks’, correlate strongly
with chronological age [5]. Moreover, for a given
chronological age, an accelerated epigenetic age or faster
rate of ageing is associated with an increased risk of
mortality and shows cross-sectional relationships with
age-related morbidities [6–10].
In this paper, we focus on six epigenetic predictors of
ageing. In 2013, Horvath developed a pan-tissue epigen-
etic clock, termed ‘Horvath Age’, derived from the linear
combination of 353 CpG sites in multiple tissues [11].
Hannum created a DNAm-based clock termed ‘Hannum
Age’ based on 71 CpG sites in blood tissue [12]. Levine
et al. proposed a predictor of lifespan and health by de-
veloping a methylation-based predictor of an individual’s
‘phenotypic age’ (‘DNAm PhenoAge’). Phenotypic age is
informed by chronological age as well as haematological
and biochemical measures, including creatinine levels
and lymphocyte percent [13]. Lu et al. proposed ‘DNAm
GrimAge’ as a predictor of mortality and demonstrated
that it outperforms existing clocks in predicting death
and age-related conditions, including cardiovascular dis-
ease [14]. DNAm GrimAge was developed in two stages.
In the first stage, DNAm-based surrogates for 88 plasma
protein levels and smoking pack years were developed
using elastic net regression models. Only DNAm-based
surrogates which exhibited a correlation coefficient of at
least 0.35 with their respective phenotype were consid-
ered for stage two. In addition to smoking pack years,
12/88 protein proxies satisfied this condition. In the
second stage, time-to-death due to all-cause mortality
was regressed on chronological age, sex, DNAm-based
surrogates for smoking pack years and 12 plasma protein
levels. The model selected chronological age, sex,
DNAm-based proxies for smoking pack years and the
levels of 7/12 plasma proteins; the linear combination of
these variables provides a measure of DNAm GrimAge.
Furthermore, telomere length is associated with cardio-
vascular disease, cancer risk and all-cause mortality [15–
17]. Lu et al. proposed a DNAm-based estimator of telo-
mere length termed ‘DNAm Telomere Length’ (DNAm
TL) which exhibits stronger associations with lifespan,
smoking history and body mass index when compared
to phenotypic telomere length as measured by quantita-
tive polymerase chain reaction or Southern blotting [18].
These five measures of biological ageing provide an
index of the difference between an individual’s biological
age and chronological age at the time of measurement
and are derived from cross-sectional measurements
across individuals of varying ages. This can approximate
a longitudinal ageing trajectory but can also be con-
founded by the possibility that individuals who were
born in different years may have been exposed to differ-
ent early-life exposures [4]. As a result, individuals of
different chronological ages may display differential
DNAm patterns that do not reflect age-related DNAm
changes but rather reflect differential early-life environ-
mental influences. To address this, Belsky et al. (2015)
developed a longitudinal measure of biological age by
examining the rate of change in 18 blood-chemistry and
organ-system-function biomarkers at three successive
time points from ages 26 to 38 in participants of the
Dunedin study (n = 954) [19]. This measure was termed
‘Pace of Aging’ (PoA), and all of the individuals in the
sample were born in 1972–1973. Recently, Belsky et al.
(2020) derived a DNAm-based proxy of PoA termed
‘DunedinPoAm’ [20]. The authors state that this meas-
ure reflects a speedometer which tracks how fast the
subject is ageing whereas the previous measures of epi-
genetic ageing represent clocks recording how much
time has passed.
For epigenetic clocks, the difference between an indi-
vidual’s methylation-based age and their chronological
age provides a measure of accelerated or decelerated
ageing. DunedinPoAm returns a measure in years of bio-
logical ageing per each calendar year with higher values
reflecting a faster rate of ageing. Higher values of Dune-
dinPoAm as well as age-adjusted Horvath Age, Hannum
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Age, DNAm PhenoAge and DNAm GrimAge are
hypothesised to associate with poorer health outcomes
as these measures capture accelerated biological ageing.
Lower values of age-adjusted DNAm TL are hypothe-
sised to correlate with poorer health as this reflects
shorter telomere length. To date, a number of studies
have demonstrated associations between epigenetic mea-
sures of ageing and risk of mortality and disease states
[21–24] or have provided comparisons of such epigen-
etic measures [25–30]. However, no study has compared
all six epigenetic measures of ageing with respect to
their association with a broad range of common health
conditions.
In this study, we test the association between the six
epigenetic measures of ageing and the prevalence, and
incidence, of the ten leading causes of mortality and dis-
ease burden (as indexed by disability-adjusted life years;
DALYs) [2, 3]. In addition, we examine their association
with continuous traits underlying these conditions, such
as lung function tests for chronic obstructive pulmonary
disease (COPD). We utilise DNA methylation array data
and electronic health record data from a Scottish cohort,
Generation Scotland: Scottish Family Health Study (GS:
SFHS or GS). GS is a family-based cohort consisting of
over 20,000 individuals with rich health and lifestyle
information. Genome-wide methylation data were gener-
ated on approximately 10,000 participants making it one
of the largest DNAm resources in the world. We exam-
ine associations between epigenetic measures of ageing
and prevalent disease as well as an assessment of their
ability to predict time-to-disease onset. These findings
may expedite the future use and refinement of large-
scale molecular data-based approaches for predicting
clinically defined outcomes and subsequent individual
disease risk prediction.
Results
Demographics and epigenetic measures of ageing
In the discovery cohort, 56.3% of the participants were
female with a mean age of 51.4 years (standard deviation
(SD) = 13.2) (n = 4450). The mean values for epigenetic
measures of ageing were as follows: Horvath age (60.1
years, SD = 9.8), Hannum age (47.4 years, SD = 9.6),
DNAm PhenoAge (43.7 years, SD = 11.5), DNAm
GrimAge (48.8 years, SD = 10.9), DNAm Telomere
Length (7.4 kilobase pairs, SD = 0.3), and DunedinPoAm
(1.1 years of biological ageing per each calendar year, SD
= 0.1). Summary data for all variables in this study are
presented in Additional file 1.
In the replication cohort, 61.4% were female with a
mean age of 50.0 years (SD = 12.5) (n = 2578). Values
for all phenotypes were comparable between discovery
and replication cohorts with the exception of DNAm
GrimAge (discovery: 48.8 years, SD = 10.9, replication:
60.5 years, SD = 10.6), and the incidence of self-reported
depression (discovery: 8.4%, replication: 16.4%), and
SCID (Structured Clinical Interview for DSM)-identified
Depression (discovery: 18.5%, replication: 38.2%). This
disparity in depression prevalence reflects an over-
sampling of depression cases in the replication cohort. It
is unclear as to why the replication cohort shows a
higher mean DNAm GrimAge. However, it is possible
that this difference may be driven by a latent aspect of
poorer overall health that may be associated or corre-
lated with depression.
Epigenetic measures of ageing and disease prevalence
In a basic model adjusting for age and sex, 51 pheno-
types were significant at Bonferroni-corrected levels of
significance in both the discovery and replication
cohorts (Additional file 2: Note 1 and Additional file 3:
Tables S1-S4). In the discovery cohort, a Bonferroni-
corrected threshold of P < 2.54 × 10-4 was applied as this
corrected for all tests performed (0.05/197 tests). Of
these 197 models, 78 were significant at P < 2.54 × 10-4
in the discovery set and were therefore carried forward
to the replication stage. In the replication set, associa-
tions which surpassed a Bonferroni-corrected threshold
of P < 6.41 × 10-4 were deemed significant (0.05/78
tests). Additional file 4: Fig. S1-S3 highlight significant
associations present in both sets for categorical traits,
continuous traits and all-cause mortality, respectively. A
measure-by-measure comparison of associations with
categorical and continuous phenotypes from fully
adjusted models in the replication cohort, stratified by
disease type, is shown in Additional file 5. For all
models, beta coefficients for continuous traits were cor-
related 0.96 between discovery and replication sets. For
categorical phenotypes, the correlation coefficient for log
odds was 0.79 between sets (Additional file 4: Fig. S4).
Fifteen relationships remained significant in both
discovery and replication sets in a fully adjusted model
accounting for age, sex and five common risk factors
(Additional file 3: Tables S5 and S6, respectively). Those
relationships which were significant in both cohorts at a
Bonferroni-corrected significance threshold of P < 6.41
× 10-4 (reflecting the same stringent threshold as above)
are reported herein and presented in Table 1 and Fig. 1.
Associations with disease
In relation to prevalent disease data, only the association
between an accelerated DNAm GrimAge and COPD
remained significant in both cohorts in the fully adjusted
model (replication cohort: odds ratio (OR) per SD =
3.29, 95% confidence interval (CI) = [1.73, 6.30], P = 3.4
× 10-4; Fig. 1)
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Associations with all-cause mortality
An accelerated DNAm GrimAge alone was associated
with all-cause mortality following adjustment for the
lifestyle risk factors (replication cohort: hazard ratio
(HR) per SD = 2.10, 95% CI = [1.36, 3.25], P = 5.6 ×
10-4; Fig. 1).
Associations with continuous clinically associated traits
An accelerated DNAm GrimAge was associated with
greater deprivation (a lower Scottish Index of Multiple
Deprivation (SIMD) rank; βreplication = -0.19, 95% CI =
[-0.25, -0.13], P = 4.6 × 10−9), an increased average heart
rate (βreplication = 0.20, 95% CI = [0.13, 0.27], P = 1.6 ×
10−8), a reduced forced expiratory flow (βreplication =
-0.15, 95% CI = [-0.21, -0.09], P = 1.4 × 10−6), a reduced
forced expiratory volume (βreplication = -0.10, 95% CI =
[-0.15, -0.05], P = 1.4 × 10−4) and increased serum cre-
atinine levels (βreplication = 0.13, 95% CI = [0.06, 0.20], P
= 2.0 × 10−4).
Higher values of DunedinPoAm, indicating a faster
rate of ageing, were positively associated with smoking
pack years (βreplication = 0.33, 95% CI = [0.28, 0.38], P =
7.6 × 10−36), greater deprivation (lower SIMD rank;
βreplication = -0.16, 95% CI = [-0.22, -0.10], P = 2.2 ×
10−8) and average heart rate (βreplication = 0.11, 95% CI =
[0.05, 0.17], P = 2.2 × 10−4).
An accelerated DNAm PhenoAge was associated with
smoking pack years (βreplication = 0.16, 95% CI = [0.11,
0.21], P = 9.5 × 10−10), an increased body mass index
(βreplication = 0.12, 95% CI = [0.07, 0.17], P = 7.4 × 10
−6)
and an increased average heart rate (βreplication = 0.12,
95% CI = [0.07, 0.17], P = 7.7 × 10−6).
Age-adjusted DNAm Telomere Length was negatively
associated with smoking pack years (βreplication = -0.18,
95% CI = [-0.23, -0.13], P = 2.7 × 10−11). An accelerated
DNAm Hannum Age (EEAA) was associated with in-
creased serum creatinine levels (βreplication = 0.13, 95%
CI = [0.08, 0.18], P = 4.2 × 10−7).
Covariate-specific attenuation
To examine the contribution of each of the five common
disease risk factors in attenuating the 51 significant
associations brought forward to the fully adjusted model,
we repeated each model including only one of these five
covariates at a time. These risk factors were alcohol con-
sumption, body mass index, deprivation, education and
Table 1 Significant and replicated relationships between epigenetic age measures and prevalent disease data, and continuous traits
Discovery cohort Replication cohort
Categorical phenotypes
Measure Variable n event OR P n event OR P
DNAm GrimAge COPD 48 2.00 1.0 × 10−4 32 3.29 3.4 × 10−4
Continuous phenotypes
Measure Variable n β P n β P
DunedinPoAm Pack Years 2419 0.45 1.2 × 10−112 1340 0.33 7.6 × 10−36
DNAm TL Pack Years 2419 -0.14 1.1 × 10−11 1340 -0.18 2.7 × 10−11
DNAm PhenoAge Pack Years 2419 0.11 3.0 × 10−08 1340 0.16 9.5 × 10−10
DNAm GrimAge SIMD 2419 -0.13 5.9 × 10−08 1340 -0.19 4.6 × 10−09
DNAm GrimAge Average Heart Rate 2416 0.19 1.4 × 10−12 1339 0.20 1.6 × 10−08
DunedinPoAm SIMD 2419 -0.13 1.8 × 10−09 1340 -0.16 2.2 × 10−08
Hannum Age Creatinine 2406 0.21 1.4 × 10−26 1334 0.13 4.2 × 10−07
DNAm GrimAge FEF 2055 -0.12 1.2 × 10−06 1149 -0.15 1.4 × 10−06
DNAm PhenoAge Body Mass Index 2419 0.12 2.5 × 10−10 1340 0.12 7.4 × 10−06
DNAm PhenoAge Average Heart Rate 2416 0.11 2.1 × 10−07 1339 0.12 7.7 × 10−06
DNAm GrimAge FEV 2074 -0.08 2.0 × 10−05 1151 -0.10 1.4 × 10−04
DNAm GrimAge Creatinine 2406 0.19 3.0 × 10−15 1334 0.13 2.0 × 10−04
DunedinPoAm Average Heart Rate 2416 0.19 1.6 × 10−15 1339 0.11 2.2 × 10−04
Mortality analysis
Measure Variable n event HR P n events HR P
DNAm GrimAge All-cause mortality 89 1.62 1.4 × 10−4 30 2.10 5.6 × 10−4
Analyses were performed using a fully adjusted model accounting for age, sex, alcohol consumption, body mass index, deprivation, education and smoking
pack years
COPD chronic obstructive pulmonary disease, FEF forced expiratory flow, FEV forced expiratory volume, HR hazard ratio, OR odds ratio, SIMD Scottish Index of
Multiple Deprivation, TL telomere length
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smoking pack years. The ranges of mean attenuation in
traits by these covariates were 9.5 to 15.1% in the discov-
ery set and 4.7 to 20.3% in the replication set (Additional
file 3: Tables S7 and S8, respectively). Smoking pack
years exhibited the greatest mean attenuation in both
cohorts (discovery = 15.1%, replication = 20.3%).
Epigenetic measures of ageing and disease incidence
For incident disease outcomes, there were 17
Bonferroni-corrected significant associations at P < 8.33
× 10−4 (P < 0.05/60 tests; full output in Additional file 3:
Table S9, see also Additional file 4: Fig. S5 and Add-
itional file 6: Note 2). Of these, 7 remained significant in
a fully adjusted model at a Bonferroni-corrected signifi-
cance threshold of 8.33 × 10−4 (Additional file 3: Table
S10). These relationships are presented herein and in
Fig. 2.
A one standard deviation increase in DNAm GrimAge
at baseline was associated with the incidence of COPD
(HR = 2.22, 95% CI = [1.81, 2.72], P = 2.4 × 10−14), type
2 diabetes (HR = 1.52, 95% CI = [1.20, 1.90], P = 3.1 ×
10−4) and heart disease (HR = 1.41, 95% CI = [1.18,
1.68], P = 1.1 × 10−4). Higher values of DunedinPoAm
(per SD) associated with the incidence of COPD (HR =
2.02, 95% CI = [1.59, 2.57], P = 8.4 × 10−9) and lung can-
cer (HR = 1.45, 95% CI = [1.18, 1.79], P = 5.3 × 10−4).
An accelerated DNAm PhenoAge (per SD) associated
with a higher incidence of type 2 diabetes (HR = 1.54,
95% CI = [1.21, 1.97], P = 4.5 × 10−4). Age-adjusted
DNAm Telomere Length (per SD) associated with a
lower incidence of heart disease (HR = 0.80, 95% CI =
[0.69, 0.92], P = 2.5 × 10−4).
Sex-specific analyses of epigenetic measures of ageing
and phenotypes in Generation Scotland
As the occurrence of common diseases differs between
the sexes, we ran sensitivity analyses using cross-
sectional data to determine the correlation between
effect sizes for males versus females. In the discovery
cohort, continuous phenotypes had a correlation
Fig. 1 The associations between epigenetic measures of ageing and disease prevalence, continuous traits and all-cause mortality in Generation
Scotland. Only associations present in discovery and replication sets are shown, and replication test statistics are presented. Continuous: Age-
adjusted DNAm GrimAge was associated with greater deprivation (lower SIMD rank), reduced forced expiratory flow and forced expiratory
volume. Age-adjusted DNAm GrimAge was positively associated with serum creatinine levels and average heart rate. Age-adjusted DNAm
PhenoAge was positively associated with body mass index, average heart rate and smoking pack years. Age-adjusted DNAm Telomere Length
was negatively associated with smoking pack years. Higher values for DunedinPoAm were associated with greater deprivation (lower SIMD rank),
a higher average heart rate and smoking pack years. Age-adjusted Hannum Age was positively associated with serum creatinine levels. Disease:
Age-adjusted DNAm GrimAge alone was associated with the prevalence of COPD in both discovery and replication sub-cohorts after correction
for multiple testing. All-Cause Mortality: Age-adjusted DNAm GrimAge alone was associated with all-cause mortality in both sets after multiple
testing correction. Associations represent a one standard deviation increase in the respective measure of biological ageing. Models were adjusted
for age, sex, alcohol consumption, body mass index, deprivation, education and smoking. Models involving lung function tests were also
corrected for height. COPD (chronic obstructive pulmonary disease), SIMD (Scottish Index of Multiple Deprivation)
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coefficient of 0.93 between sexes whereas categorical
disease phenotypes exhibited a correlation coefficient of
0.81 (Additional file 4: Fig. S6). In the replication co-
hort, there was a correlation of 0.86 and 0.70 between
effect sizes for continuous and categorical phenotypes,
respectively (Additional file 4: Fig. S7). Excluding
diseases ≤ 10 cases (lung and bowel cancer), the largest
difference between males and females was for the
DunedinPoAm-chronic kidney disease relationship
(males: no. of events = 40, OR = 1.23, females: no. of
events = 45, OR = 1.72, absolute difference = 0.49). On
average, the largest difference between males and
females across measures was observed for COPD with
males having a higher odds ratio for each measure of
ageing (mean difference in effect sizes across measures
= 0.25, range = [0.12, 0.37], discovery cohort;
Additional file 3: Table S11).
Discussion
In this study, we examined associations between six
major epigenetic measures of ageing and the prevalence
and incidence of the leading causes of mortality and dis-
ease burden in high-income countries. DNAm GrimAge,
a predictor of mortality, associated with the prevalence
of COPD and incidence of various disease states, includ-
ing COPD, type 2 diabetes and cardiovascular disease. It
was associated with death due to all-cause mortality and
outperformed competitor epigenetic measures of ageing
in capturing variability across clinically associated con-
tinuous traits. Higher values for DunedinPoAm, which
captures faster rates of biological ageing, associated with
the incidence of COPD and lung cancer. Higher-than-
expected DNAm PhenoAge predicted the incidence of
type 2 diabetes in the present study. Age-adjusted
measures of DNAm Telomere Length associated with
the incidence of ischemic heart disease. Our results
replicate previous cross-sectional findings between
DNAm PhenoAge and body mass index, diabetes [21]
and socioeconomic position (in a basic model) [28]. We
also replicated associations between DNAm GrimAge
and heart disease [14]. Lastly, we replicated the relation-
ship between Hannum Age and creatinine [31] and be-
tween DNAmTLadjAge and smoking pack years [18].
This is also the first external study examining the associ-
ation between DunedinPoAm and a wide range of health
outcomes.
Fig. 2 The associations between epigenetic measures of ageing and incidence of common disease states in Generation Scotland. Age-adjusted
DNAm GrimAge was associated with the incidence of COPD, type 2 diabetes and ischemic heart disease after 13 years of follow-up. Age-adjusted
DNAm PhenoAge associated with the incidence of type 2 diabetes. Age-adjusted measures of DNAm Telomere Length associated with the
incidence of ischemic heart disease. Higher DunedinPoAm values, indicating a faster pace of ageing, were associated with the incidence of COPD
and lung cancer. Associations represent a one standard deviation increase in the respective epigenetic measure of ageing. Models were adjusted
for age, sex, alcohol consumption, body mass index, deprivation, education and smoking. COPD (chronic obstructive pulmonary disease)
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DNAm GrimAge served as a powerful correlate of
various phenotypes in our study and has been previously
shown to associate with incident heart disease, time-to-
cancer and neurological health [14, 22]. DNAm
GrimAge is derived from chronological age, sex and
methylation-based surrogates of smoking pack years and
seven plasma proteins (including DNAm-based estima-
tors of plasminogen activator inhibitor 1, growth differ-
entiation factor 15 and cystatin C). Here, we show that
this blood-based epigenetic predictor of mortality risk is
associated with poorer performance in lung function
tests and predicted incidence of COPD. Compromised
lung function has previously been linked to mortality
[32, 33]. While it is possible that the associations are
mainly driven by the inclusion of smoking pack years,
DNAm GrimAge remained associated with COPD and
spirometry tests when controlling for self-reported
smoking pack years. Similarly, DunedinPoAm associated
with time-to-onset of COPD and lung cancer. Dunedin-
PoAm also demonstrated a strong correlation with
smoking pack years in our study; however, the associa-
tions between DunedinPoAm and incident disease out-
comes remained after adjusting for common disease risk
factors, including smoking behaviour. In their original
study, Belsky et al. identified that the AHRR probe
cg05575921 was among the 46 CpG sites used to calcu-
late DunedinPoAm. This probe has been strongly associ-
ated with smoking behaviour [34–41]. The authors also
demonstrated that a version of DunedinPoAm calculated
without this probe correlated 0.94 with the Dunedin-
PoAm measure including all probes [20]. DNAm Pheno-
Age predicted the incidence of type 2 diabetes; however,
this may reflect the inclusion of HbA1c in the pheno-
typic age measure which is used to diagnose diabetes. In
our study, an epigenetic predictor of telomere length
predicted time-to-onset of ischemic heart disease. A
shorter leukocyte telomere length has been shown to
associate with heart disease in diverse populations, sug-
gesting that the DNAm Telomere Length predictor may
capture key facets of this clinical association [42–44].
Our rich resource of genome-wide DNA methylation
and longitudinal health data is the first to show the asso-
ciation of epigenetic measures of ageing with a wide
range of common disease states, even after accounting
for major confounding influences. These findings have
implications for the potential utility of epigenetic mea-
sures of ageing in clinical settings.
The majority of our prevalent disease data relied on
self-report. Self-report prevalence data have been shown
to have a high degree of sensitivity and specificity [45].
Our incident data was obtained using ICD-10 codes
from health record linkage. Strikingly, measures of
biological ageing showed strong associations with the in-
cidence of common diseases following 13 years of
follow-up from the study baseline. These measures
performed better at predicting incident rather than
prevalent data. However, this may reflect the inclusion
of health record-linked versus self-report data and the
larger sample size in incidence analyses. Notably, the six
epigenetic measures of ageing in our study are correlated
with one another among study participants. As well as
this, the incidence or prevalence of different disease
states, as well as associated continuous traits, may be
correlated with one another as they may reflect patterns
of poor overall health and disease risk behaviours.
Therefore, our application of Bonferroni-corrected sig-
nificance thresholds is stringent and only captured the
most high-confidence associations in our study. These
associations were also independent of common disease
risk factors and therefore may reflect important associa-
tions between age-related physiological changes and risk
of disease.
An important limitation is the lack of adjustments for
medication use, which may confound associations
between epigenetic measures and chronic conditions.
Furthermore, studies examining causality between the
relationships shown are merited. It is also unclear
whether the risk factors examined in this study play a
causal role in driving associations between epigenetic
measures of ageing and phenotypes, or whether these
pleiotropically affect altered DNA methylation and
adverse health outcomes. Genetic influences may
contribute to differences in DNA methylation and the
subsequent estimation of epigenetic age or pace of
ageing; therefore, it is possible that our findings may not
be generalisable to individuals of non-European ancestry
[46, 47].
Conclusions
In conclusion, using a large cohort with rich health and
DNA methylation data, we provide the first comparison
of six major epigenetic measures of biological ageing
with respect to their associations with leading causes of
mortality and disease burden. DNAm GrimAge outper-
formed the other measures in its associations with dis-
ease data and associated clinical traits. This may suggest
that predicting mortality, rather than age or homeostatic
characteristics, may be more informative for common
disease prediction. Thus, proteomic-based methods (as
utilised by DNAm GrimAge) using large, physiologically
diverse protein sets for predicting ageing and health may
be of particular interest in future studies. Our results
may help to refine the future use and development of
biological age estimators, particularly in studies which
aim to comprehensively examine their ability to predict
stringent clinically defined outcomes. Our analyses sug-
gest that epigenetic measures of ageing can predict the
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incidence of common disease states, even after account-
ing for major confounding risk factors. This may have
significant implications for their potential utility in clin-
ical settings to complement gold-standard methods of
clinical disease assessment and management.
Methods
Generation Scotland
Details of the Generation Scotland (GS) study have been
described previously [48, 49]. Briefly, the cohort includes
23,960 individuals, where most individuals (94.2%) have
at least one other first-degree family member participat-
ing in the study. This encompasses 5573 families with a
median family size of 3 (interquartile range = 2–5 mem-
bers; excluding 1400 singletons without any relatives in
the study). For prevalence analyses, the discovery cohort
comprised unrelated GS participants with genome-wide
methylation data (ndiscovery = 4450). The replication co-
hort was also derived from GS participants, unrelated to
those in the discovery cohort, who had genome-wide
DNA methylation measured in a separate batch (n =
5087). Within the replication cohort, 2578 participants
were also unrelated to one another and these unrelated
individuals were considered for cross-sectional analyses
(nreplication = 2578). For incidence analyses, all individuals
with available methylation and phenotypic data in GS
were considered (n = 4450 + 5087 = 9537).
DNA methylation and calculation of biological ageing
measures
DNA methylation levels were measured using the Illu-
mina HumanMethylationEPIC BeadChip Array on blood
samples from GS participants. Further details on the
processing of DNAm data and the calculation of the six
measures of ageing, or pace of ageing, are outlined in
Additional file 7; the five clocks (other than Dunedin-
PoAm) were calculated using Horvath’s online age calcu-
lator (https://dnamage.genetics.ucla.edu/). Normalised
GS methylation data were uploaded as input for the al-
gorithm. Data underwent a further round of normalisa-
tion by the age calculator. Briefly, Horvath Age provides
an estimate of biological ageing termed “intrinsic epigen-
etic age acceleration (IEAA)” as it is independent of age-
related changes in blood composition. IEAA is derived
from regressing Horvath Age onto chronological age. In
contrast, Hannum Age provides a measure of ageing re-
ferred to as “extrinsic epigenetic age acceleration
(EEAA)” as it encompasses age-related changes in blood
cell composition. EEAA is derived from regressing a
weighted average of Hannum Age and three blood cell
types (naive and exhausted cytotoxic T cells, and plas-
mablasts) onto chronological age. DNAm PhenoAge re-
flects an individual’s ‘Phenotypic Age’ and, when
regressed onto chronological age, provides an index of
age acceleration termed ‘AgeAccelPheno’. Similarly,
when age-adjusted, DNAm GrimAge is termed ‘AgeAc-
celGrim’. Lastly, age-adjusted ‘DNAm Telomere Length’
is referred to as ‘DNAmTLadjAge’. DunedinPoAm was
calculated using DNAm beta values as input and the
DunedinPoAm38 package in R developed by the original
study’s authors (https://github.com/danbelsky/Dunedin-
PoAm38 [20]). The five aforementioned epigenetic
clocks capture a state of accelerated or decelerated bio-
logical ageing reflecting how much ageing has occurred
in the individual. However, DunedinPoAm was trained
to provide a single time-point, blood-based measure-
ment of the pace of biological ageing in individuals.
DunedinPoAm is a DNAm-based proxy of the ‘Pace of
Aging’ (PoA) measure. PoA was derived by examining
the rate of change in 18 blood-chemistry and organ-
system-function biomarkers at three successive time
points in participants of Dunedin Study (n = 954). The
participants were all born in 1972–1973 and were aged
26, 32 and 38 at the time of biomarker measurements.
Mixed-effects growth modelling of longitudinal changes
in biomarker levels among participants allowed for esti-
mations of the rate of change in biomarker levels for
each participant. The sum of random slopes for the bio-
marker levels (rate of change for each participant) pro-
vided a measure of PoA [19]. An elastic net regression
model using DNAm data and PoA calculated at age 38
in participants of the Dunedin Study identified 46 CpG
sites as informative for predicting PoA, thereby creating
a single time-point measure of PoA called Dunedin-
PoAm. DunedinPoAm reflects years of biological ageing
per each calendar year. These six measures of biological
ageing were input as independent variables in statistical
models. Correlations between these predictors are
shown in Additional file 4: Fig. S8 for the discovery and
replication sets. The correlation structure between these
predictors was similar in both sets. DNAmTLadjAge was
negatively correlated with the other five indices of ageing
(discovery: mean coefficient = − 0.34, range = − 0.12 to
− 0.47). This negative correlation was present as shorter
telomere lengths typically correspond to an advanced
age. The mean correlation coefficient between the
remaining five predictors was 0.35 (discovery: range =
0.07 to 0.73).
Phenotype preparation
For continuous phenotypes, outliers were defined as
those values which were beyond 3.5 standard deviations
from the mean for a given trait. These outliers were
removed prior to analyses. Body mass index was log-
transformed. To reduce skewness in the distribution of
alcohol consumption and smoking pack years, a log(u-
nits +1) or log(pack years +1) transformation was
performed. The interval from the start of the Q wave to
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the end of the T wave on electrocardiogram tests (QT
interval) was corrected for heart rate. A general fluid
(‘gf’) cognitive ability score was derived from principal
components analysis of three tests examining different
cognitive domains. These domains were processing
speed (Wechsler Digit Symbol Substitution Test), verbal
declarative memory (Wechsler Logical Memory Test)
and verbal fluency (the phonemic verbal fluency test).
To derive a general (‘g’) cognitive ability score, the prin-
cipal component analysis was performed on the above
three tests and a measure of crystallised intelligence:
The Mill Hill Vocabulary test. The first unrotated princi-
pal components from these analyses were extracted and
labelled as ‘gf’ and ‘g’, respectively.
For categorical phenotypes, we aimed to examine
the ten leading causes of mortality in high-income
countries [2]. We also aimed to examine the ten lead-
ing causes of disease burden, six of which overlap
with the top causes of mortality. This represents four-
teen diseases. We had self-report phenotypic informa-
tion for the prevalence of nine of these diseases
(Additional file 1); specifically, we lacked self-report
information on lower respiratory diseases and kidney
disease (mortality), skin and sense organ diseases (dis-
ease burden), and Alzheimer’s disease (AD; present in
both the leading causes of mortality and disease bur-
den). We were able to use proxy phenotypes for two
of these conditions. We used self-reported maternal
history and paternal history as proxies for AD. For
kidney disease, we estimated glomerular filtration rate
(eGFR) from serum creatinine levels using the chronic
kidney disease epidemiology collaboration CKD-EPI
equation [50] from which we inferred the prevalence
of chronic kidney disease (CKD). Individuals with an
eGFR < 60 ml/min/1.73 m2 were considered to have
CKD. In addition to self-report depression, we also
had available information on SCID (Structured Clin-
ical Interview for DSM)-identified depression [51].
Lastly, we separated self-reported back and neck pain
into distinct phenotypes for analyses. Together, this
resulted in a total of fourteen disease phenotypes for
prevalence analyses.
In relation to disease incidence, health record linkage
was available for up to 13 years of follow-up since the
study baseline (median time-of-onset from baseline =
5.75 years, range = [< 1 month, 13 years]). For each dis-
ease state, those individuals who self-reported disease at
study baseline were excluded. For cancer, individuals
present on the Scottish Cancer Registry (SMR06) were
included as cases for incidence analyses. Additionally,
for incident cancer analyses, individuals who were
recorded on the General Acute Inpatient and Day Case -
Scottish Morbidity Records (SMR01) were removed
from the control set. For a given condition, individuals
who self-reported no disease at study baseline but had
prior evidence of diagnosis through health record link-
age were removed from analyses. Discovery and replica-
tion cohorts were combined to consider all participants
for follow-up and to provide a sufficient number of cases
for analyses. For incident disease analyses, ICD-10-coded
data were retrieved for the following ten conditions: AD,
bowel cancer, breast cancer, COPD, depression, type 2
diabetes, dorsalgia (neck and back pain combined), is-
chemic heart disease, lung cancer and stroke. These re-
flect the disease states examined in the prevalence
analyses with the exception of chronic kidney disease.
Furthermore, the two proxies of AD, two measures of
depression and separate measures of neck and back pain
were replaced by single, clinically defined counterparts
in the incidence analyses. Additional file 4: Fig. S9 shows
a heatmap for effect sizes from Cox regression models
between epigenetic measures of ageing and incident dis-
ease outcomes in a fully adjusted model.
Statistical analyses
Linear regression models were used to examine the asso-
ciation between continuous traits and age-adjusted
epigenetic clock measures (reflecting the difference be-
tween an individual’s estimated biological age and
chronological age) or DunedinPoAm (reflecting the rate
of biological ageing). In cross-sectional analyses, logistic
regression was used to test the association between
categorical disease phenotypes and these epigenetic mea-
sures of ageing. In longitudinal analyses, Cox propor-
tional hazards regression models were used to examine
whether measures of biological ageing were associated
with the incidence of disease. Cox models were also used
to examine whether these measures were associated with
all-cause mortality in discovery and replication cohorts.
There were 182 (4.09%) and 57 (2.25%) deaths in the
discovery and replication sets, respectively. The propor-
tional hazards assumption was tested using the cox.zph()
function in the survival package in R [52, 53]. There was
no strong evidence (P > 0.05) of assumption violation
for the reported significant associations. Phenotypes
were scaled to mean zero and unit variance. Continuous
or categorical phenotypes were input as dependent vari-
ables with measures of biological ageing incorporated as
independent variables.
In a basic model, all analyses were adjusted for
chronological age and sex. Additional adjustments for
height were carried out for measures of lung function.
All significant tests from the basic model were then re-
peated adjusting for additional five covariates, which
represent important risk factors for common diseases.
These covariates were alcohol intake (units consumed/
week), body mass index, educational attainment,
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deprivation (Scottish Index of Multiple Deprivation) and
tobacco smoking pack years.
a. Basic model: Phenotype ~ Epigenetic Measure + age
+ sex
b. Fully adjusted model: Phenotype ~ Epigenetic
Measure + age + sex + alcohol units consumed per
week + body mass index + educational attainment
+ Scottish Index of Multiple Deprivation + smoking
pack years
In relation to cross-sectional prevalence data, the dis-
covery analyses consisted of 33 phenotypes which were
tested against every epigenetic measure of ageing (all-
cause mortality, fourteen disease and eighteen continu-
ous phenotypes; Additional file 3: Table S1). This led to
a total of 198 (33 × 6 measures) tests; however, the
DNAm GrimAge versus smoking pack years comparison
was excluded given the inclusion of a DNAm-based sur-
rogate of pack years in the development of DNAm
GrimAge. This led to a Bonferroni-corrected significance
threshold of P < 0.05/197 tests = 2.54 × 10-4. Of these
197 tests, 78 were significant; thus, in the replication co-
hort, a Bonferroni-corrected significance threshold of P
< 0.05/78 tests = 6.41 × 10−4 was set. In total, 51 associa-
tions were significant in both cohorts. The fully adjusted
model was then applied to these 51 associations in both
the discovery and replication cohorts, holding the same
stringent Bonferroni-corrected threshold of P < 0.05/78
tests = 6.41 × 10−4.
In relation to incidence data, all ten phenotypes were
tested against each of the six measures of ageing. In the
basic model, this resulted in a Bonferroni-corrected sig-
nificance threshold of P < 0.05/60 tests = 8.33 × 10−4. In
total, seventeen associations were significant and
brought forward to the fully adjusted analysis stage. In
the fully adjusted model, the same Bonferroni-corrected
significance threshold of P < 0.05/60 tests = 8.33 × 10-4
was applied.
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